Literature DB >> 22718644

Stability of osteopontin in plasma and serum.

Patrizia Lanteri1, Giovanni Lombardi, Alessandra Colombini, Dalila Grasso, Giuseppe Banfi.   

Abstract

BACKGROUND: Osteopontin is a glycoprotein widely expressed in many tissues and in different physiological conditions. Osteopontin concentrations are usually measured through immunological methods; however, little is known about the pre-analytical management of the sample. We evaluated the effects of different times and temperatures storage conditions on serum and plasma concentrations of osteopontin.
METHODS: Serum and plasma aliquots were frozen at – 80° C, following storage at 4° C or room temperature for 0, 2, 4, 8, 12, 24 and 48 h. Osteopontin concentrations were determined by enzymoimmunometric assay. Serum samples obtained from tubes with or without gel separator were compared to verify the effect of gel. Western blotting analysis was performed to characterize the antibody.
RESULTS: Osteopontin concentrations were stable over time in all conditions in both serum and plasma. Plasma showed 3.8 – 4.8-fold higher concentrations than serum. Comparable levels were found between serum tubes with or without gel separator and always lower than those in plasma, demonstrating no effect of gel in serum tubes. Western blotting analysis showed various osteopontin bands, indicating that the antibody recognizes the entire panel of different osteopontin forms.
CONCLUSIONS: We demonstrated the stability across 48 h of osteopontin in serum and plasma at either room temperature or 4° C, when the evaluation is carried out by an immune-based method. The minimal variations observed over time were always lower than the calculated intra- and inter-assay coefficients of variation. Plasma specimens should be preferred when osteopontin concentration are assayed by immunological methods.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22718644     DOI: 10.1515/cclm-2012-0177

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  10 in total

Review 1.  Novel bone metabolism-associated hormones: the importance of the pre-analytical phase for understanding their physiological roles.

Authors:  Giovanni Lombardi; Mosè Barbaro; Massimo Locatelli; Giuseppe Banfi
Journal:  Endocrine       Date:  2017-02-08       Impact factor: 3.633

Review 2.  Measuring myokines with cardiovascular functions: pre-analytical variables affecting the analytical output.

Authors:  Giovanni Lombardi; Veronica Sansoni; Giuseppe Banfi
Journal:  Ann Transl Med       Date:  2017-08

3.  Patterns of Osteopontin Expression in Abusive Head Trauma Compared with Other Causes of Pediatric Traumatic Brain Injury.

Authors:  Laura S Blackwell; Margaret Martinez; Ashley Fournier-Goodnight; Janet Figueroa; Andrew Appert; Atul Vats; Bushra Wali; Iqbal Sayeed; Andrew Reisner
Journal:  J Pediatr       Date:  2020-07-02       Impact factor: 4.406

4.  Methodical and pre-analytical characteristics of a multiplex cancer biomarker immunoassay.

Authors:  Natalie Hermann; Katja Dreßen; Frank A Schildberg; Christopher Jakobs; Stefan Holdenrieder
Journal:  World J Methodol       Date:  2014-12-26

5.  Plasma osteopontin may predict neuroinflammation and the severity of pediatric traumatic brain injury.

Authors:  Ning Gao; Xiaohui Zhang-Brotzge; Bushra Wali; Iqbal Sayeed; Joshua J Chern; Laura S Blackwell; Chia-Yi Kuan; Andrew Reisner
Journal:  J Cereb Blood Flow Metab       Date:  2019-03-13       Impact factor: 6.200

6.  Osteopontin as a biomarker for COVID-19 severity and multisystem inflammatory syndrome in children: A pilot study.

Authors:  Andrew Reisner; Laura S Blackwell; Iqbal Sayeed; Hannah E Myers; Bushra Wali; Stacy Heilman; Janet Figueroa; Austin Lu; Laila Hussaini; Evan J Anderson; Andi L Shane; Christina A Rostad
Journal:  Exp Biol Med (Maywood)       Date:  2021-09-26

7.  Osteopontin Is a Blood Biomarker for Microglial Activation and Brain Injury in Experimental Hypoxic-Ischemic Encephalopathy.

Authors:  Yikun Li; Eric B Dammer; Xiaohui Zhang-Brotzge; Scott Chen; Duc M Duong; Nicholas T Seyfried; Chia-Yi Kuan; Yu-Yo Sun
Journal:  eNeuro       Date:  2017-01-10

8.  Osteopontin is a prognostic biomarker in non-small cell lung cancer.

Authors:  Ane Kongsgaard Rud; Kjetil Boye; Miriam Oijordsbakken; Marius Lund-Iversen; Ann Rita Halvorsen; Steinar K Solberg; Gisle Berge; Aslaug Helland; Odd Terje Brustugun; Gunhild M Mælandsmo
Journal:  BMC Cancer       Date:  2013-11-11       Impact factor: 4.430

9.  Osteopontin Is Upregulated in Human and Murine Acute Schistosomiasis Mansoni.

Authors:  Thiago Almeida Pereira; Wing-Kin Syn; Frederico Figueiredo Amâncio; Pedro Henrique Diniz Cunha; Julia Fonseca Morais Caporali; Guilherme Vaz de Melo Trindade; Elisângela Trindade Santos; Márcia Maria Souza; Zilton Araújo Andrade; Rafal P Witek; William Evan Secor; Fausto Edmundo Lima Pereira; José Roberto Lambertucci; Anna Mae Diehl
Journal:  PLoS Negl Trop Dis       Date:  2016-10-18

10.  Dextranol: An inert xeroprotectant.

Authors:  Bryan J Jones; Advitiya Mahajan; Alptekin Aksan
Journal:  PLoS One       Date:  2019-09-06       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.